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Abstract
Background: For patients with painful knee osteoarthritis, long-term symptomatic relief may improve quality of life.
Cooled radiofrequency ablation (CRFA) has demonstrated significant improvements in pain, physical function and
health-related quality of life compared with conservative therapy with intra-articular steroid (IAS) injections. This study
aimed to establish the cost-effectiveness of CRFA compared with IAS for managing moderate to severe osteoarthritis-
related knee pain, from the US Medicare system perspective.
Methods: We conducted a cost-effectiveness analysis utilizing efficacy data (Oxford Knee Scores) from a randomized,
crossover trial on CRFA (NCT02343003), which compared CRFA with IAS out to 6 and 12months, and with IAS patients
who subsequently crossed over to receive CRFA after 6 months. Outcomes included health benefits (quality-adjusted
life-years [QALYs]), costs and cost-effectiveness (expressed as cost per QALY gained). QALYs were estimated by mapping
Oxford Knee Scores to the EQ-5D generic utility measure using a validated algorithm. Secondary analyses explored
differences in the settings of care and procedures used in-trial versus real-world clinical practice.
Results: CRFA resulted in an incremental QALY gain of 0.091 at an incremental cost of $1711, equating to a cost of
US$18,773 per QALY gained over a 6-month time horizon versus IAS. Over a 12-month time horizon, the incremental
QALY gain was 0.229 at the same incremental cost, equating to a cost of US$7462 per QALY gained versus IAS. Real-
world cost assumptions resulted in modest increases in the cost per QALY gained to a maximum of US$21,166 and
US$8296 at 6 and 12months, respectively. Sensitivity analyses demonstrated that findings were robust to variations in
efficacy and cost parameters.
Conclusions: CRFA is a highly cost-effective treatment option for patients with osteoarthritis-related knee pain,
compared with the US$100,000/QALY threshold typically used in the US.
Keywords: Cost-utility analysis, QALY, Economic analysis, CRFA, Intra-articular steroid, Oxford knee score
Background
Symptomatic knee osteoarthritis is a non-inflammatory
degenerative disease that can cause substantial pain and
negatively impact patients’ usual activities, affecting more
than 9 million adults in the US [1]. In addition to reducing
health-related quality of life, knee osteoarthritis is a major
economic burden with surgical treatment options alone
estimated to cost around US$12 billion a year [2] and the
societal impact of absenteeism resulting from osteoarth-
ritis estimated at a similar value [3].
Arthroplasty is an effective and established terminal
therapeutic option for late-stage osteoarthritis-related pain
and dysfunction [4, 5]; however, the procedure may not be
appropriate in all patients due to co-morbidities, lack of
social support, or other factors [6, 7]. Intra-articular ster-
oid (IAS) injections are often considered a first-line inva-
sive treatment and can provide short-term pain relief, but
may require repeated treatment, and may cause cartilage
damage when used over an extended period [8, 9].
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: drdesai@isppcenter.com
1International Spine Pain and Performance Center, Washington, DC, USA
Full list of author information is available at the end of the article
Desai et al. BMC Musculoskeletal Disorders          (2019) 20:302 
https://doi.org/10.1186/s12891-019-2681-2
Outpatient-delivered radiofrequency ablation of targeted
genicular nerves has emerged as a realistic, minimally-
invasive procedural option for patients with pain associated
with knee osteoarthritis [10–12]. In particular, Coolief™
System (Avanos Medical, Alpharetta, GA, USA), the cooled
form of radiofrequency ablation (CRFA), is an effective and
safe long-term therapeutic option for managing pain and
improving physical function and health-related quality of
life in patients with knee osteoarthritis [13–17] and to date
is the only radiofrequency treatment to be approved by the
FDA for management of osteoarthritis knee pain.1
In a randomized, controlled, open-label, multicenter,
crossover trial (NCT02343003), CRFA reduced knee pain
(measured by numeric rating scale) by at least 50% in 74%
of subjects compared with 16% of subjects treated with
IAS injection (p < 0.0001) at 6months’ follow up [14], with
improvements in knee pain in the CRFA arm sustained
out to 12months [13]. Similarly, CRFA resulted in signifi-
cant improvements in Oxford Knee Score (OKS) at both 6
and 12months post-treatment [13, 14]. Moreover, subjects
originally randomized to IAS who were then treated with
CRFA (crossover) at 6months (n = 58), after being dissatis-
fied with their IAS treatment, subsequently achieved
statistically-significant and clinically-relevant pain relief
and functional improvements [13].
Although the comparative clinical effectiveness and
safety of CRFA has been clearly demonstrated, no studies
have yet assessed the cost-effectiveness of this procedure.
Cost-effectiveness analysis is a standard approach for esti-
mating the resources used (costs) and the health benefits
achieved for a medical intervention compared with an
alternative strategy.
The current study aimed to evaluate the cost-
effectiveness of CRFA compared with IAS injection for
moderate to severe pain due to knee osteoarthritis from
the US Medicare system perspective, by way of a deci-
sion analysis model utilizing outcomes from clinical trial
NCT02343003 and costs from routine practice.
Methods
Economic analysis overview
The cost-effectiveness analysis was developed in Microsoft
Excel to evaluate the costs and health outcomes of patients
undergoing CRFA or IAS. The analysis was based on the
pivotal clinical trial NCT02343003 [13, 14], and mirrored
the trial in terms of the interventions compared, the time-
horizon considered, the procedures performed and the set-
tings of care in which patients were managed. Comparative
efficacy data (mean OKS) from the trial were used to deter-
mine health gains achieved by patients undergoing each
therapy in terms of quality-adjusted life-years (QALYs).
Costs were estimated from the US Medicare perspective.
The primary outcome was the cost per QALY gained,
which captures both the health gains and healthcare costs
associated with treatment. We calculated this incremental
cost-effectiveness ratio (ICER) as the difference in total
cost between CRFA and IAS injection, divided by the
difference in QALYs. ICER values were calculated where
CRFA resulted in health benefits (increased QALYs) at an
increased total cost.
Economic analysis design
Clinical study NCT02343003 was a prospective, random-
ized, open-label, multicenter crossover trial and has been
reported in detail by Davis et al. [13, 14]. The population
considered in the economic analysis reflected the popula-
tion enrolled in the trial, being patients with radiographic
confirmation of grade 2 to 4 knee osteoarthritis within 12
months prior to study screening and knee pain for 6
months or more that was unresponsive to conservative
treatments. Other inclusion criteria included: numeric
rating scale pain score of 6 or greater for the index knee;
OKS of 35 or less; positive diagnostic genicular nerve block,
defined as a decrease of ≥50% in numeric rating scale score;
if taking an opioid or other morphine-equivalent medica-
tion, the dose must have been clinically stable.
In the trial, subjects were randomized 1:1 to receive
CRFA (N = 76) utilizing the Coolief™ System (Avanos
Medical, Alpharetta, GA, USA) or a single IAS injection
with corticosteroid (N = 75), and were assessed at study
baseline and at 1, 3, 6 and 12months post-intervention
[13, 14]. The ablation technique has been described in
detail previously [13, 14]. The crossover design allowed
any subject who was dissatisfied with their IAS treatment
after their 6-month visit, which may have included an in-
crease in knee pain, to choose to cross over and receive
CRFA treatment [13]. Crossover subjects were assessed at
7, 9 and 12months post-study baseline (corresponding
with 1, 3 and 6months post CRFA treatment).
Our primary economic analysis compared CRFA with
IAS, using time-horizons of either 6 or 12months post-
treatment, consistent with the interventions and follow up
periods within the trial. The analysis did not extend
beyond this timeframe as to do so would have required as-
sumptions to be made as to the durability of the treatment
effect and the need for re-treatment beyond this time-
frame, and introduced uncertainty into the analysis. In line
with the trial, our primary analysis assumed that patients
received one intervention with either CRFA or IAS at
study baseline and the benefits and costs included in the
analysis reflect those associated with this baseline inter-
vention. No repeat treatments were included. In a second-
ary analysis (12-month crossover scenario), the CRFA
group was also compared with the crossover group out to
12months; in this analysis, all patients in the crossover
group received IAS at baseline, followed by CRFA at 6
months. Costs and benefits were not discounted because
the time horizon was only 6–12months.
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All patients screened for the trial underwent diagnos-
tic genicular nerve block to determine their potential to
respond to CRFA, and thus determine their eligibility for
trial inclusion; 233 patients were screened, of which 151
met the inclusion criteria for the trial, with six failing to
achieve a positive genicular nerve block response (3.8%).
Due to the high costs associated with a genicular nerve
block (Table 3) we have included this screening test in
our cost analysis. In clinical practice, this would only
need to be performed for patients who were going to
receive CRFA and not those treated with IAS, and
therefore we have conservatively applied the cost of
genicular nerve block to the CRFA arm only. In this
CRFA arm, we assumed that 96.2% of subjects (those
who had a positive response to the nerve block)
accrued the costs and benefits associated with CRFA,
whereas 3.8% who failed to achieve a positive re-
sponse were assumed to receive the costs and clinical
benefits associated with IAS.
Clinical inputs and health utilities
The economic model calculated health benefits in the
form of QALYs by mapping from trial-based changes in
knee function, as measured using mean OKS. The OKS
is a widely used measure of knee function and pain
which was developed and validated to assess patient out-
comes following knee replacement [18] and has been
employed across trials, cohort studies and audits [19].
The OKS captures patients’ assessment of knee symp-
toms and function with 12 questions which can be
scored from 0 (worst function) through to 4 (best func-
tion), with a total possible score ranging between 0 and
48 [14, 19].
To enable the use of OKS in the economic analysis
and allow the estimation of health gains in the form of
QALYs, OKS data was converted into utility scores using
a published mapping algorithm. Utilities range from 1
(perfect health) to zero (death). The EQ-5D is the most
widely-used utility measure employed in studies that es-
timate QALYs [20] and is preferred by health technology
assessment bodies, such as the National Institute for
Health and Care Excellence and the Canadian Agency
for Drugs and Technologies in Health [21, 22]. Mapping
has become a well-recognized method to estimate util-
ities for use in economic analyses, and involves statisti-
cally predicting utilities from a condition-specific
measure, such as the OKS [23]. We utilized mean OKS,
as reported in the clinical trial, and mapped these to
EQ-5D utility scores using a validated mapping algo-
rithm estimated by Dakin et al. [24] that maps to utilities
using the UK time trade off EQ-5D (3 level) tariff [25].
Although Dakin et al. also estimated a response mapping
with better prediction accuracy, we used a simple model
reported in the same paper which allowed us to use
mean OKS without patient-level data.
Predicted EQ−5D utility ¼ −0:0404485þ 0:0224412
mean OKS
Where mean OKS =mean OKS value from trial
population.
Standard errors around mapped utilities were estimated
using the spreadsheet tool accompanying the OKS algo-
rithm [24] using methods described by Lawrence et al.
[26]. For the primary 6- and 12-month comparisons of
CRFA with IAS, we utilized mean OKS results from the
full analysis set as per the clinical trial primary analysis
[13, 14] (Table 1); 58 and 67 subjects had OKS data avail-
able for analysis in the CRFA and IAS arms, respectively,
at the 6-month follow up [14]. Fifty-two subjects in the
CRFA arm and 3 subjects in the IAS arm completed the
study in their original arm and had OKS data at the 12-
month follow-up [13].
For the secondary 12-month crossover scenario, OKS
data for the CRFA arm was modelled as per the primary
economic analysis. For the crossover arm, we used mean
OKS data across all patients randomized to the IAS arm
out to 3months (as per the primary analysis, Table 1), after
which time we used mean OKS for the IAS subjects who
crossed over to CRFA out to 12months; post-crossover
OKS data were derived from the per-protocol dataset,
as per the 12-month clinical trial analysis [13]. Mean
OKS and estimated utility scores are provided in Table
1 for CRFA and IAS groups and in Table 2 for the
crossover group.
We assumed that utilities changed linearly between
follow-up times and calculated QALYs as the area under
the curve.
Costs
Costs were derived from Centers for Medicare and Me-
dicaid Services fee schedules [27], and included standard
physician (in-office or in-hospital) and hospital payments
for IAS, CRFA and genicular nerve block procedures.
The reference year for costs was 2017. All costs consid-
ered in the analysis were assumed to be accrued at the
point when patients received their CRFA or IAS inter-
vention. In line with the trial protocol, we assumed that
patients would not receive a repeat treatment with
CRFA or IAS or arthroplasty during the 6 to 12-month
time horizon. Although some subjects in both treatment
arms required analgesic medication (opioid and non-
opioid) at baseline and throughout the clinical study,
there were no significant differences between treatment
arms, except for a statistically significant reduction in
non-opioid analgesia dose in the CRFA arm at 6 months
[13, 14]. Costs of analgesia were therefore conservatively
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excluded from our analysis. We assumed that following
treatment, patients would be discharged to home with
instructions for self-care. In practice, patients in both
arms may have subsequent nurse follow up and physio-
therapy; it was assumed that this pathway of care would
be the same for both treatment arms and hence costs
for these contacts were excluded from the analysis.
Primary analyses reflected the settings of care and pro-
cedures administered in the clinical trial (Summary costs:
Table 3; Unit costs: see Additional file 1: Table S1). The
cost applied for the CRFA procedure assumed that the
procedure was done in a hospital outpatient setting and
comprised ablation of the index knee at three anatomic lo-
cations, using fluoroscopic visualization of anatomical
landmarks for accurate CRF probe placement, consistent
with the procedures and settings of care utilized in the
trial [13, 14]. Similarly, for the IAS procedure, costs were
estimated assuming patients received one corticosteroid
injection in the index knee using ultrasound guidance in a
hospital outpatient visit. All subjects in the trial under-
went genicular nerve block to determine their potential to
respond to CRFA, and thus determine their eligibility for
trial inclusion; as such this cost was also included in the
analysis for all patients in the CRFA arm, assuming an
outpatient setting (See “Economic analysis study design”).
Patients in the IAS arm were assumed not to receive nerve
block, consistent with clinical practice. In the crossover
scenario, we assumed that all patients in the crossover
arm would receive genicular nerve block.
Secondary cost analyses (Real-world cost scenarios 1
and 2) were also conducted to account for any differ-
ences likely to be encountered in clinical practice. Real-
world cost scenario 1 assumed that IAS was adminis-
tered in the office setting without the need for ultra-
sound guidance, to better reflect clinical practice for this
procedure. Real-world cost scenario 2 assumed that both
IAS and genicular nerve block (for CRFA) would be per-
formed in the office setting rather than the hospital out-
patient setting; this scenario is likely to be most
reflective of real-world settings for CRFA, IAS and nerve
block procedures in US clinical practice.
Data analysis and sensitivity analysis
Conclusions are based on a US$100,000 per QALY thresh-
old based on the current benchmark published by the In-
stitute for Clinical and Economic Review in the US [28].
The intervention is deemed cost-effective if the ICER falls
below this threshold and not cost-effective otherwise.
One-way sensitivity analyses were conducted to assess
the sensitivity of the model results to changes in efficacy
and cost inputs. For all model parameters, except for costs,
the minimum and maximum plausible values for one-way
analysis were defined as the lower and upper 95% confi-
dence limits. No measure of uncertainty was available for
costs and so the plausible range was defined based on ±
10% of the mean (See Additional file 1: Table S2). Results
of one-way sensitivity analyses were depicted on tornado
diagrams, showing how changes in individual model inputs
Table 1 OKS and predicted utility scores (EQ-5D)a: used to model CRFA and IAS in primary analysis
Baselineb Month 1 Month 3 Month 6 Month 12
CRFA IAS CRFA IAS CRFA IAS CRFA IAS CRFA IAS
OKS Mean (SD) 16.7 (4.4) 16.9 (5.1) 33.3 (9.2) 29.4 (8.5) 34.6 (8.3) 24.6 (7.6) 35.7 (8.8) 22.4 (8.5) 34.3 (11.1) 22.0 (16.6)
Sample sizec 76 75 67 69 65 68 58 67 52 3
SE 0.50 0.59 1.13 1.03 1.02 0.93 1.16 1.04 1.54 9.61
Mapped
EQ-5D
Mean (SE) 0.335
(0.029)
0.340
(0.030)
0.708
(0.033)
0.619
(0.031)
0.735
(0.032)
0.512
(0.030)
0.761
(0.035)
0.463
(0.032)
0.729
(0.042)
0.453
(0.238)
Abbreviations: CRFA cooled radiofrequency ablation, IAS intra-articular steroid, OKS Oxford Knee Score, SD standard deviation, SE standard error
aIncludes all available observations
bTime points as per clinical trial NCT02343003
cSample size represents subjects with available data at each time point. Based on full analysis set from clinical trial NCT02343003
Table 2 OKS and predicted utility scores (EQ-5D): used to model the crossover arma
Study Month 6b Study Month 7b Study Month 9b Study Month 12b
OKS Mean (SD) 18.6 (6.6) 30.0 (9.4) 30.3 (10.0) 29.8 (10.6)
Sample sizec 42 40 38 37
SE 1.02 1.49 1.62 1.74
Mapped EQ-5D Mean (SE) 0.377 (0.042) 0.633 (0.043) 0.640 (0.046) 0.628 (0.049)
Abbreviations: CRFA cooled radiofrequency ablation, IAS intra-articular steroid, OKS Oxford Knee Score, SD standard deviation, SE standard error
aBased on the clinical trial NCT02343003, subjects in the IAS arm were able to cross over to CRFA at study Month 6 and continued to be followed up at study
Month 7, 9 and 12. Data shown for those patients in the IAS arm who received CRFA at month 6
bTime points as per clinical trial
cSample size represents only subjects who crossed over from IAS to CRFA at 6 months, with available data at each time point (based on per protocol analysis set)
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between plausible minimum and maximum values influ-
enced the ICER. We quantified the uncertainty around the
conclusions using probabilistic sensitivity analyses, in
which all parameters were varied independently except for
the utility mapping coefficients, which were correlated
[24]. Costs were assumed to follow gamma distributions,
assuming that the ±10% plausible range equaled the 95%
confidence interval, and clinical inputs were varied using a
using a normal distribution defined by their mean and SE.
Results of probabilistic sensitivity analyses were depicted
on scatter plots on the cost-effectiveness plane, showing
the distribution of ICERs generated from 10,000 replicates.
In addition, cost-effectiveness acceptability curves depict
probabilistic sensitivity analyses results by showing the
probability that CRFA would be cost-effective versus IAS,
over a range of monetary values that a decision-maker
may be willing to pay per QALY.
Subjects in the trial arms were well-matched at baseline,
although there was a small, non-significant imbalance in
baseline OKS between the CRFA and IAS groups, with the
IAS group having a slightly more favorable OKS [14],
equating to a slightly higher baseline mean utility score; we
adjusted for this difference in a sensitivity analysis, by using
the mean baseline OKS for the overall trial population and
applying the relative change from baseline for each arm.
Sub-group analyses were not presented for other trial end-
points [13, 14], and hence we did not consider any specific
patient sub-groups in our economic analyses.
Results
Primary analyses
At a time-horizon of 6 months post-treatment, CRFA was
associated with a 0.091 gain in QALYs and an incremental
cost of US$1711 compared with IAS. CRFA therefore cost
US$18,773 per QALY gained (Table 4). Extending the time
horizon to 12months reduced the ICER to US$7462 per
QALY, reflecting the sustained benefit of CRFA compared
with IAS over 12months (QALY gain 0.229), while treat-
ment costs are all accrued at the point of treatment.
Secondary analyses
In the 12-month crossover scenario, patients in the IAS
crossover group gained the clinical benefit of CRFA from
6months onwards but accrued the cost of IAS at Month
0 and that of CRFA at Month 6. In this scenario, CRFA
was dominant over IAS/CRFA crossover (more effective
and less costly), gaining 0.134 QALYs and saving
$294.52 compared with IAS/CRFA crossover.
Real-world costing scenarios 1 and 2 generated ICERs
that were all below $22,000 per QALY (Table 5). Scenario
1 represents the most conservative cost analysis (IAS in-
office not outpatient, nerve block only applied to CRFA
patients and still performed in outpatient setting), whereas
scenario 2 is likely most representative of the real-world
setting (IAS in-office not outpatient, nerve block only
applied to CRFA patients but performed in-office).
One-way sensitivity analyses
Adjusting for the small differences in baseline utility be-
tween CRFA and IAS groups had a minimal impact on re-
sults, reducing the ICER to $17,827 per QALY at 6months
and $7308 per QALY at 12months.
One-way sensitivity analyses demonstrated that the
ICER was relatively insensitive to variations in key pa-
rameters (Fig. 1). The top 10 parameters generating the
most variation in the ICER were changes in OKS (CRFA
and IAS at 1, 3 and 6months) and hospital procedure
payments for CRFA (1st, 2nd, 3rd nerve) and IAS.
Probabilistic sensitivity analysis
Results of the probabilistic sensitivity analysis for CRFA
versus IAS at 6 and 12months are depicted in Fig. 2 and
Additional file 1: Figure S1. At a US$100,000 per QALY
threshold, CRFA has an 86% probability of being cost-
effective at 6 months and 95% at 12 months (Fig. 2).
Discussion
Although the effectiveness and safety of CRFA in relieving
pain and improving patient function in patients with symp-
tomatic knee osteoarthritis has been clearly demonstrated
in a randomized clinical trial [13, 14], to our knowledge,
our study is the first to assess the cost-effectiveness of
CRFA.
Using CRFA resulted in significant improvements in
OKS versus IAS, which translated into ICERs below
US$19,000 per QALY at 6months and US$8000 per QALY
at 12months. The estimates reflect the sustained benefit of
CRFA observed over 12months, while the effect of IAS ap-
pears to wane. Analyses also included the cost of genicular
nerve block, a diagnostic tool used to determine the poten-
tial responsiveness to ablation. Although nerve block was
used on all trial subjects irrespective of therapy received
Table 3 Total treatment costs applied in the economic analysis (US$)a
Primary analyses Real-world cost scenario 1 Real-world cost scenario 2
CRFA procedure 1497.50 (OP) 1497.50 (OP) 1497.50 (OP)
IAS procedure 294.52 (OP) 67.73 (IO) 67.73 (IO)
Genicular nerve block 553.85 (OP) 553.85 (OP) 175.86 (IO)
Abbreviations: CRFA cooled radiofrequency ablation, IAS intra-articular steroid, IO in-office, OP outpatient
aBased on appropriate Current Procedural Terminology codes, assuming physician and hospital outpatient department payments
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(CRFA or IAS), it would have been inappropriate to include
the costs of nerve block in the IAS arm in our analysis. As
such, we assumed that only patients in the CRFA arm re-
ceived nerve block and accrued the associated cost. Modi-
fying the cost assumptions to reflect real-world clinical
practice, including administration of IAS in-office without
ultrasound guidance (versus outpatient facility using ultra-
sound) and genicular nerve block for CRFA patients given
in-office (versus outpatient consultation), did not change
the overall conclusion that CRFA is highly cost-effective
versus IAS. All ICERs were well below the benchmark
threshold of US$100,000 per QALY recommended in the
US [28], representing the maximum amount that a
decision-maker may be willing to pay for the health bene-
fits provided by the treatment. Sensitivity analyses demon-
strated the economic evaluation to be robust to variation
in data inputs, and that there was a > 85% chance that
CRFA is cost-effective compared with IAS at the US$100,
000 per QALY threshold.
Utilizing data from the IAS-CRFA crossover group
facilitated a comparison of early versus delayed CRFA,
in which crossover patients accrued health benefits
from CRFA post-IAS failure, but were attributed the
cost of both IAS and CRFA treatment. This prelimin-
ary 12-month analysis suggested that immediate
CRFA treatment may be cost-saving and offer greater
QALY gains, compared with delaying CRFA until fail-
ure of IAS. The analysis included only those patients
in the IAS arm who were dissatisfied and chose to
switch; further evidence is required to robustly assess
the cost-effectiveness of giving IAS first-line and of-
fering CRFA only to those patients who fail
treatment.
We are not aware of any previous economic evaluations
on CRFA or any randomized trials comparing CRFA with
interventions other than IAS, such as hyaluronic acid
injections or other ablation techniques. Further research is
required to examine how CRFA compares with other
techniques from a clinical and an economic perspective.
Our analysis utilized trial data from a US multicenter
study and took a US Medicare cost perspective. Although
we are not aware of any evidence to suggest that the
health benefits achieved by patients undergoing CRFA
relative to IAS may be different for different geographic
populations, differences in healthcare settings, clinical
practice and associated costs mean that further research is
required to assess cost-effectiveness in other countries.
Our findings should be interpreted considering several
limitations. First, the 12-month CRFA-IAS analysis is
limited by the large number of subjects who were dissat-
isfied with IAS after 6 months and who crossed over to
receive CRFA, which resulted in only three subjects
remaining in the IAS arm and having OKS data available
at the 12-month follow up [13]. However, the treatment
effect of IAS appeared to wane from Month 1 through
to Month 6 post-treatment, whereas CRFA appears to
have a durable effect out to 12months. As such, more
robust effectiveness data for IAS at 12 months (with lar-
ger sample sizes) would be unlikely to affect the overall
conclusion that CRFA is cost-effective at a 12-month
Table 4 Primary analysis, CRFA vs IAS 6- and 12-month time horizon: deterministic mean (probabilistic sensitivity analysis mean; 95%
confidence interval)
Time horizon Intervention QALYs Incremental QALY gain Costs (US$) Incremental cost (US$) Cost per QALY gained (US$)a
6 months CRFA 0.347 (0.345;
0.265, 0.420)
0.091 (0.090;
−0.024, 0.198)
$2005 ($2005;
$1929, $2083)
$1711 ($1711;
$1632, $1791)
$18,773 ($19,053;
−$58,845, $91,604)
IAS 0.256 (0.255;
0.174, 0.335)
$295 ($294;
$275, $315)
12-months CRFA 0.714 (0.706;
0.543, 0.853)
0.229 (0.230;
0.011, 0.440)
$2005 ($2005;
$1929, $2083)
$1711 ($1711;
$1632, $1791)
$7462 ($7424;
$3189, $31,405)
IAS 0.485 (0.475;
0.323, 0.630)
$295 ($294;
$275, $315)
Abbreviations: CRFA cooled radiofrequency ablation, IAS intra-articular steroid, QALY quality-adjusted life-years
aCost per QALY gained for the comparison of CRFA with IAS
Table 5 Secondary analyses: deterministic mean differences between CRFA versus IAS
Analysis Incremental QALY gain Incremental cost (US$) Cost per QALY gained (US$)
Real world cost scenario 1: IAS in-office, CRFA outpatient, nerve block only applied to CRFA group and still performed in outpatient setting
6-month time horizon 0.091 1929.97 21,166
12-month time horizon 0.229 1929.97 8296
Real world cost scenario 2: IAS in-office, CRFA outpatient, nerve block only applied to CRFA patients but performed in-office
6-month time horizon 0.091 1550.98 17,564
12-month time horizon 0.229 1550.98 6768
Abbreviations: CRFA cooled radiofrequency ablation, IAS intra-articular steroid, QALY quality-adjusted life-years
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time horizon. Second, longer-term comparative clinical
studies would allow estimates of cost-effectiveness
beyond 12 months to be generated. Third, the trial
and our economic analysis did not allow for repeat
treatments, or switching to alternate treatments in
the case of waning treatment effect. Although the
CRFA treatment effect appears to be maintained to
12 months, CRFA may be repeated more frequently in
practice, while the need for re-treatment beyond 12
months is unclear. Meta-analysis suggests that IAS
can be effective for at least 16–24 weeks [9], while
one study reported using a 3-monthly injection fre-
quency over 2 years [8]. Further research may provide
insight into the optimal timing of re-treatment with
CRFA or IAS that can be incorporated into future
cost-effectiveness analyses. Fourth, we excluded costs
other than screening and treatment, consistent with
the trial where all subjects were discharged to home
with instructions for self-care. Follow-up costs, such
as nurse follow-up and physiotherapy may be ex-
pected, however the improved effectiveness and dur-
ability of CRFA versus IAS would make it likely that
these costs would be higher for IAS-treated patients.
No significant differences in analgesia use between
trial arms were observed, except for a significant re-
duction in non-opioid dose with CRFA at 6 months
[14]. Overall, these cost exclusions would likely mean
that the current analysis is conservative.
Fig. 1 One-way sensitivity analysis, CRFA vs IAS (6-month time horizon). Abbreviations: CRFA cooled radiofrequency ablation, IAS intra-articular
steroid, OKS Oxford Knee Score. Vertical line denotes incremental cost-effectiveness ratio for primary analysis
Fig. 2 Cost-effectiveness acceptability curves CRFA vs IAS (6- and 12-month time horizons). Abbreviations: CRFA cooled radiofrequency ablation,
IAS intra-articular steroid, QALY quality-adjusted life-year
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Conclusions
In patients with symptomatic knee osteoarthritis, signifi-
cant improvements in patient function with CRFA translate
into health-related quality of life gains as early as 1month,
compared with conservative therapy with IAS injections.
From the US Medicare perspective, CRFA is an efficacious
and cost-effective treatment option for patients with
osteoarthritis-related knee pain.
Endnotes
1FDA 510(k): K163461
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